14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
RGNX vs VYGR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, REGENXBIO Inc. (RGNX) is the stronger overall head-to-head candidate over Voyager Therapeutics, Inc. (VYGR) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). RGNX carries a Unified Composite Score of 45.3/100 (HOLD) at $7.47 (N/M Forward P/E, -120.4% operating margin), whereas VYGR carries 46.3/100 (HOLD) at $1.67 (8.4x Forward P/E, -436.2% operating margin).
Composite vs. Pillar Nuance: While VYGR currently prints a higher short-term Unified Composite Score (46.3/100 HOLD vs. RGNX 45.3/100 HOLD), RGNX captures the overall institutional head-to-head verdict (5–5 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-120.4% vs. -436.2% operating margin) and revenue trajectory (-69.2% vs. -70.0% YoY).
Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile VYGR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $102.7M market capitalization and -436.2% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ RGNX vs VYGR Key Questions & Quantitative Answers
As of Nov 16, 2026, REGENXBIO Inc. (RGNX) is the stronger overall head-to-head candidate over Voyager Therapeutics, Inc. (VYGR) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). RGNX carries a Unified Composite Score of 45.3/100 (HOLD) at $7.47 (N/M Forward P/E, -120.4% operating margin), whereas VYGR carries 46.3/100 (HOLD) at $1.67 (8.4x Forward P/E, -436.2% operating margin). Composite vs. Pillar Nuance: While VYGR currently prints a higher short-term Unified Composite Score (46.3/100 HOLD vs. RGNX 45.3/100 HOLD), RGNX captures the overall institutional head-to-head verdict (5–5 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-120.4% vs. -436.2% operating margin) and revenue trajectory (-69.2% vs. -70.0% YoY). Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile VYGR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
RGNX leads the Growth & Scale pillar: RGNX posts -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin), compared with VYGR at -70.0% YoY revenue growth and +0.0% YoY earnings growth on $25M TTM revenue (N/A gross margin, -436.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RGNX cumulative revenue shifted -22.7% while VYGR shifted +300.0%. In operating R&D and SG&A reinvestment, RGNX deploys 55.9% of Rev ($86M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VYGR.
VYGR screens cheaper on headline valuation multiples. RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin), whereas VYGR trades at 8.4x Forward P/E, 8.4x Trailing P/E, N/M PEG, and 3.4x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RGNX (-113.2% ROE) versus VYGR (-58.9% ROE) capital efficiency.
In options market volatility and institutional positioning, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.81β · 76% Vol realized risk). By comparison, VYGR carries 130.1% implied volatility (31st %ile, Balanced (25th–60th %ile)), a 2.35x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.43β · 85% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.